BeiGene Ltd. ADR | Ownership
Companies that own BeiGene Ltd. ADR
Baker Bros. Advisors LP
11,959,824
20.23%
0
13.81%
08/02/2018
Hillhouse Capital Management Ltd. (Hong Kong)
5,472,259
9.26%
0
10.93%
06/30/2018
Fidelity Management & Research Co.
5,315,829
8.99%
-6,453
0.1%
06/30/2018
Wellington Management Co. LLP
2,467,866
4.18%
-1,032,513
0.08%
06/30/2018
Temasek Holdings Pte Ltd. (Investment Management)
2,270,100
3.84%
0
0.89%
06/30/2018
Capital Research & Management Co. (World Investors)
1,828,239
3.09%
1,292,029
0.05%
06/30/2018
T. Rowe Price Associates, Inc.
1,417,078
2.4%
-2,572
0.03%
06/30/2018
Canada Pension Plan Investment Board
995,000
1.68%
0
0.16%
06/30/2018
The Vanguard Group, Inc.
958,534
1.62%
-33,886
0.01%
06/30/2018
PRIMECAP Management Co.
857,333
1.45%
-166
0.1%
06/30/2018
| Address |
Zhongguancun Life Science Park
Beijing Beijing 102206
China
|
|
Employees
|
- |
| Website |
http://www.beigene.com |
| Updated |
07/08/2019 |
| BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. |
